{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["68(5)"],"submitter":["Sebastian M"],"funding":["CureVac AG"],"pubmed_abstract":["CV9201 is an RNActive<sup>®</sup>-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalation trial, 46 patients with locally advanced (n = 7) or metastatic (n = 39) NSCLC and at least stable disease after first-line treatment received five intradermal CV9201 injections (400-1600 µg of mRNA). The primary objective of the trial was to assess safety. Secondary objectives included assessment of antibody and ex vivo T cell responses against the five antigens, and changes in immune cell populations. All CV9201 dose levels were well-tolerated and the recommended dose for phase IIa was 1600 µg. Most AEs were mild-to-moderate injec"],"journal":["Cancer immunology, immunotherapy : CII"],"pagination":["799-812"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11028316"],"repository":["biostudies-literature"],"pubmed_title":["A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer."],"pmcid":["PMC11028316"],"pubmed_authors":["Fotin-Mleczek M","Reck M","Mayer F","Sebastian M","von Boehmer L","Kallen KJ","Muth A","Thomas M","Bernhard H","Lander T","Gnad-Vogt U","Schneller F","Hong HS","Groschel A","Hoerr I","Knuth A","Koch SD","Probst J","von der Muelbe F","Zippelius A","Strack T","Stohlmacher J","Scheel B","Wiegand V","Schroder A","Atanackovic D"],"additional_accession":[]},"is_claimable":false,"name":"A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.","description":"CV9201 is an RNActive<sup>®</sup>-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalation trial, 46 patients with locally advanced (n = 7) or metastatic (n = 39) NSCLC and at least stable disease after first-line treatment received five intradermal CV9201 injections (400-1600 µg of mRNA). The primary objective of the trial was to assess safety. Secondary objectives included assessment of antibody and ex vivo T cell responses against the five antigens, and changes in immune cell populations. All CV9201 dose levels were well-tolerated and the recommended dose for phase IIa was 1600 µg. Most AEs were mild-to-moderate injec","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 May","modification":"2025-04-22T20:46:28.12Z","creation":"2025-04-06T03:16:22.978Z"},"accession":"S-EPMC11028316","cross_references":{"pubmed":["30770959"],"doi":["10.1007/s00262-019-02315-x"]}}